Baird Medical Accelerates Global Commercial Roadmap with Strategic Clinical Education Initiatives in the U.S. and Japan

Baird Medical (NASDAQ: BDMD) announced clinical education programs in the U.S. and Japan to accelerate global adoption of its Microwave Ablation (MWA) technology for benign thyroid tumors.

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) announced clinical education programs in the U.S. and Japan to accelerate global adoption of its Microwave Ablation (MWA) technology for benign thyroid tumors. The company led advanced training at Columbia University and a workshop at Showa Medical University to standardize interventional thyroidology techniques and expand non-surgical patient options.

Argus Feb 9 session

+9.73% close to close Open Argus

Details

News Market Reaction – BDMD

On Feb 9, the day this news came out, BDMD closed 9.73% above the previous close.

Data tracked by StockTitan Argus for the Feb 9 session.

Key Figures

Warrant shares registered: 11,500,000 shares Resale shares registered: 34,415,562 shares Warrant exercise price: US$11.50 per share +5 more

Warrant shares registered

11,500,000 shares

Ordinary shares issuable upon exercise of public warrants

Resale shares registered

34,415,562 shares

Ordinary shares registered for resale by existing shareholders

Warrant exercise price

US$11.50 per share

Exercise price of public warrants

Share price reference

US$1.63

Nasdaq share price on December 4, 2025 cited in filing

Resale share proportion

70.9%

Resale shares as portion of shares outstanding after exercises/conversions

Current price

US$0.9294

Pre-news trading level on latest close

52-week high

US$7.2616

Pre-news 52-week high

52-week low

US$0.901

Pre-news 52-week low

Historical Context

5 past events · Latest: Jan 28

5 events

1. Jan 28

   Clinical education event

   24h Move

   +6.9%

   Gynecology microwave ablation masterclass to train physicians across Asia.

2. Jan 26

   Strategic partnership

   24h Move

   +0.0%

   Partnership to use Hainan Free Trade Port as hub for global commercialization.

3. Jan 20

   Investor conference

   24h Move

   -0.9%

   JP Morgan Healthcare Conference meetings to discuss strategy and MWA adoption.

4. Jan 07

   Regulatory approvals

   24h Move

   +3.9%

   Product registrations in Pakistan and Vietnam enabling new market entries.

5. Dec 17

   Manufacturing expansion

   24h Move

   +2.2%

   Establishment of U.S. manufacturing base with MPS Medical for global supply.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

microwave ablation, interventional thyroidology, benign thyroid tumors, public warrants, +1 more

5 terms

microwave ablation medical

"a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced"

Microwave ablation is a medical procedure that uses focused microwave energy to heat and destroy abnormal tissue, such as tumors, through a needle-like probe inserted into the body; think of it as using a tiny, targeted microwave oven to cook away problem cells without large incisions. It matters to investors because it represents a growing category of minimally invasive treatments that can reduce hospital stays, create demand for specialized devices and disposables, and influence reimbursement and adoption trends in healthcare markets.

interventional thyroidology medical

"accelerate its global expansion by establishing standardized clinical excellence for interventional thyroidology."

Interventional thyroidology is the medical field that treats thyroid problems using minimally invasive procedures—such as image-guided needle therapies, thermal or chemical ablation, and targeted drainages—instead of open surgery. For investors, it matters because these procedures drive demand for specialized devices, training, and outpatient services, can lower costs and recovery time for patients, and influence reimbursement and market growth for companies supplying the equipment and clinics.

benign thyroid tumors medical

"Microwave Ablation System for the treatment of Benign Thyroid Tumors."

Benign thyroid tumors are noncancerous lumps in the thyroid gland, the small hormone-making organ in the neck; they do not invade nearby tissue or spread to other organs. They matter to investors because how often they occur, how they are detected, and how they are treated affects demand for diagnostic tools, drugs and procedures—similar to a common, manageable household repair that creates predictable ongoing business for companies in healthcare and biotech.

public warrants financial

"ordinary shares issuable upon exercise of public warrants at US$11.50 per share"

Public warrants are tradable securities that give the holder the right to buy a company’s stock at a fixed price before a set expiration date. Like a coupon that lets you purchase shares later at a preset price, they matter to investors because using them can bring new cash into the company but also increase the total number of shares outstanding, which can dilute existing ownership and influence the stock’s price and potential gains.

hfCAA regulatory

"warns that HFCAA-related auditor inspection issues could eventually lead to a Nasdaq delisting"

The HFCAA is a U.S. law that requires companies listed on U.S. stock exchanges to allow their auditors to be inspected by U.S. regulators; if a company’s auditors can’t be reviewed for several years, the company risks being removed from U.S. markets. For investors, it matters because the law increases transparency and audit oversight—think of it as a safety inspection for a car—while also creating a clear regulatory trigger that can affect a stock’s availability and price if compliance can’t be shown.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Feb. 9, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the execution of premier clinical education programs in the United States and Japan. These strategic engagements reinforce Baird Medical's market leadership and accelerate its global expansion by establishing standardized clinical excellence for interventional thyroidology.

In New York, the Company successfully facilitated an advanced training initiative at the Columbia University Irving Medical Center, led by Dr. Jennifer Kuo, Director of the Interventional Endocrinology Program and Fellowship Director at Columbia University. This high-level collaboration empowered distinguished specialists Dr. Todd Frieze and Dr. Alberto Monreal from Duke Health, to refine techniques in minimally invasive therapies, including Baird Medical´s Microwave Ablation System for the treatment of Benign Thyroid Tumors. By leveraging Dr. Kuo's expertise, Baird Medical empowers top-tier institutions to adopt and standardize advanced ablation procedures, expanding patient access to non-surgical options.

Simultaneously, Baird Medical solidified its presence in Asia through a high-profile workshop at Showa Medical University in Yokohama. Opening with remarks from Professor Nobuhiro Fukunari and featuring insights from Professor Ming-An Yu of the China-Japan Friendship Hospital, the event fostered critical academic exchange. This initiative underscores the Company's commitment to driving the adoption of thyroid ablation across international markets through peer-to-peer education.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-accelerates-global-commercial-roadmap-with-strategic-clinical-education-initiatives-in-the-us-and-japan-302682296.html

SOURCE BDMD

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What clinical education did Baird Medical (BDMD) run at Columbia University on Feb 9, 2026?

Baird Medical conducted an advanced training initiative at Columbia University led by Dr. Jennifer Kuo. According to the company, the program trained specialists from top centers to refine minimally invasive Microwave Ablation techniques for benign thyroid tumors.

How does the BDMD workshop in Yokohama support Baird Medical's Asia expansion?

The Yokohama workshop at Showa Medical University fostered academic exchange with regional experts. According to the company, the event aimed to drive adoption of thyroid ablation across Asia via peer-to-peer clinical education and local institutional engagement.

Which physicians participated in Baird Medical's U.S. training for BDMD technology?

Participants included Dr. Jennifer Kuo, Dr. Todd Frieze, and Dr. Alberto Monreal in the U.S. program. According to the company, these specialists refined minimally invasive ablation procedures using Baird Medical's Microwave Ablation System.

What clinical focus did Baird Medical (BDMD) emphasize in its recent programs?

The programs emphasized standardized interventional thyroidology and non-surgical treatment of benign thyroid tumors. According to the company, the training targeted technique refinement and broader patient access to MWA therapies.

What is the investor relevance of Baird Medical's (BDMD) training initiatives?

The initiatives aim to accelerate clinical adoption and international market presence for MWA technology. According to the company, standardized training at leading institutions supports commercial rollout and broader clinical acceptance over time.